Angiotensin II Receptor Blockers (ARBs) Guideline Summary

Introduction to ARBs

• The American College of Cardiology recommends the use of Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension, with available options including azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan 1

Clinical Applications of ARBs

• ARBs are indicated for the treatment of hypertension, with all currently available ARBs being FDA-approved for this condition 1
• The American Heart Association suggests that candesartan, losartan, and valsartan have demonstrated benefits in heart failure 2, 3
• ARBs reduce microalbuminuria and improve renal function in diabetic patients, according to the American Journal of Kidney Diseases 4

Safety and Precautions

• The American College of Cardiology warns of the risk of hyperkalemia in patients with chronic kidney disease (CKD) or those on potassium-sparing medications when using ARBs 1
• ARBs should be avoided during pregnancy due to fetal toxicity, as recommended by the American College of Cardiology 1
• The American Heart Association notes that angioedema can still occur with ARBs, although less commonly than with ACE inhibitors 3

Comparative Efficacy and Guideline Recommendations

• The American Heart Association suggests that ARBs remain an important class of medications for cardiovascular and renal protection, with specific selection often guided by comorbidities, dosing convenience, and individual patient response 5, 6